<SEC-DOCUMENT>0000947871-24-000492.txt : 20240517
<SEC-HEADER>0000947871-24-000492.hdr.sgml : 20240517
<ACCEPTANCE-DATETIME>20240517150829
ACCESSION NUMBER:		0000947871-24-000492
CONFORMED SUBMISSION TYPE:	144
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20240517
DATE AS OF CHANGE:		20240517

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Enliven Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001672619
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				811523849
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		144
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	001-39247
		FILM NUMBER:		24959189

	BUSINESS ADDRESS:	
		STREET 1:		6200 LOOKOUT ROAD
		CITY:			BOULDER
		STATE:			CO
		ZIP:			80301
		BUSINESS PHONE:		720-647-8519

	MAIL ADDRESS:	
		STREET 1:		6200 LOOKOUT ROAD
		CITY:			BOULDER
		STATE:			CO
		ZIP:			80301

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	IMARA Inc.
		DATE OF NAME CHANGE:	20160419

REPORTING-OWNER:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ORBIMED ADVISORS LLC
		CENTRAL INDEX KEY:			0001055951
		ORGANIZATION NAME:           	
		IRS NUMBER:				133976876
		STATE OF INCORPORATION:			DE

	FILING VALUES:
		FORM TYPE:		144

	BUSINESS ADDRESS:	
		STREET 1:		601 LEXINGTON AVENUE
		STREET 2:		54TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10022
		BUSINESS PHONE:		(212) 739-6400

	MAIL ADDRESS:	
		STREET 1:		601 LEXINGTON AVENUE
		STREET 2:		54TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10022
</SEC-HEADER>
<DOCUMENT>
<TYPE>144
<SEQUENCE>1
<FILENAME>primary_doc.xml
<TEXT>
<XML>
<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/ownership" xmlns:com="http://www.sec.gov/edgar/common">
  <headerData>
    <submissionType>144</submissionType>
    <filerInfo>
      <filer>
        <filerCredentials>
          <!-- Field: Pseudo-Tag; ID: Name; Data: ORBIMED ADVISORS LLC -->
          <cik>0001055951</cik>
          <ccc>XXXXXXXX</ccc>
        </filerCredentials>
      </filer>
      <liveTestFlag>LIVE</liveTestFlag>



    </filerInfo>
  </headerData>
  <formData>
    <issuerInfo>
      <issuerCik>0001672619</issuerCik>
      <issuerName>Enliven Therapeutics, Inc.</issuerName>
      <secFileNumber>001-39247</secFileNumber>
      <issuerAddress>
        <com:street1>6200 Lookout Road</com:street1>
        <com:city>Boulder</com:city>
        <com:stateOrCountry>CO</com:stateOrCountry>
        <com:zipCode>80301</com:zipCode>
      </issuerAddress>
      <issuerContactPhone>720-647-8519</issuerContactPhone>
      <nameOfPersonForWhoseAccountTheSecuritiesAreToBeSold>OrbiMed Private Investments VII, LP</nameOfPersonForWhoseAccountTheSecuritiesAreToBeSold>
      <relationshipsToIssuer>
        <relationshipToIssuer>Director</relationshipToIssuer>
        <relationshipToIssuer>Shareholder</relationshipToIssuer>
      </relationshipsToIssuer>
    </issuerInfo>
    <securitiesInformation>
      <securitiesClassTitle>Common Stock</securitiesClassTitle>
      <brokerOrMarketmakerDetails>
        <name>Morgan Stanley &amp; Co. LLC</name>
        <address>
          <com:street1>1585 Broadway</com:street1>
          <com:city>New York</com:city>
          <com:stateOrCountry>NY</com:stateOrCountry>
          <com:zipCode>10036</com:zipCode>
        </address>
      </brokerOrMarketmakerDetails>
      <noOfUnitsSold>1000000</noOfUnitsSold>
      <aggregateMarketValue>22140000.00</aggregateMarketValue>
      <noOfUnitsOutstanding>47036698</noOfUnitsOutstanding>
      <approxSaleDate>05/16/2024</approxSaleDate>
      <securitiesExchangeName>Nasdaq</securitiesExchangeName>
    </securitiesInformation>
    <securitiesToBeSold>
      <securitiesClassTitle>Common Stock</securitiesClassTitle>
      <acquiredDate>02/23/2023</acquiredDate>
      <natureOfAcquisitionTransaction>Merger</natureOfAcquisitionTransaction>
      <nameOfPersonfromWhomAcquired>Issuer</nameOfPersonfromWhomAcquired>
      <isGiftTransaction>N</isGiftTransaction>
      <amountOfSecuritiesAcquired>1000000</amountOfSecuritiesAcquired>
      <paymentDate>02/23/2023</paymentDate>
      <natureOfPayment>N/A</natureOfPayment>
    </securitiesToBeSold>
    <nothingToReportFlagOnSecuritiesSoldInPast3Months>Y</nothingToReportFlagOnSecuritiesSoldInPast3Months>
    <remarks>OrbiMed Capital GP VII LLC is the general partner of OrbiMed Private Investments VII, LP. OrbiMed Advisors LLC is the managing member of OrbiMed Capital GP VII LLC.</remarks>
    <noticeSignature>
      <noticeDate>05/17/2024</noticeDate>
      <signature>/s/ Douglas Coon, Chief Compliance Officer, OrbiMed Advisors LLC, managing member of the general partner of OrbiMed Private Investments VII, LP</signature>
    </noticeSignature>
  </formData>
</edgarSubmission>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
